Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (521-530 of 692) with videos related to

Pageof 70
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Cancer Cell|December 30, 2014
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3KβSarit Schwartz, John Wongvipat, Cath B Trigwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumorsMargaret M Centenera, Joanna L Gillis, Adrienne R Hanson, et al.
Annals of Neurology|December 21, 2005
Migraine and MTHFR C677T genotype in a population-based sampleAnn I Scher, Gisela M Terwindt, W M Monique Verschuren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerHoward I Scher, Glenn Heller, Arturo Molina, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
Cancer Cell|July 23, 2019
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune SuppressionWenjing Su, Hyun Ho Han, Yan Wang, et al.
Pageof 70

Showing results (521-530 of 692) with videos related to

Sort By:
Pageof 70
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Cancer Cell|December 30, 2014
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3KβSarit Schwartz, John Wongvipat, Cath B Trigwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2012
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumorsMargaret M Centenera, Joanna L Gillis, Adrienne R Hanson, et al.
Annals of Neurology|December 21, 2005
Migraine and MTHFR C677T genotype in a population-based sampleAnn I Scher, Gisela M Terwindt, W M Monique Verschuren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerHoward I Scher, Glenn Heller, Arturo Molina, et al.
JAMA Oncology|March 10, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical TrialDana E Rathkopf, Tomasz M Beer, Yohann Loriot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
Cancer Cell|July 23, 2019
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune SuppressionWenjing Su, Hyun Ho Han, Yan Wang, et al.
Pageof 70